Search clinical trials for: Sarcomere Mutations

Total 1200 results

HealthCore-NERI
National Heart, Lung, and Blood Institute (NHLBI)

Completed

Valsartan for Attenuating Disease Evolution In Early Sarcomeric HCM (VANISH)

Hypertrophic Cardiomyopathy

United States, Canada
Pauls Stradins Clinical University Hospital

Recruiting

Latvian Early Atherosclerosis Registry

Coronary Artery Disease | Atherosclerosis, Coronary

Latvia
Shanghai JMT-Bio Inc.

Not yet recruiting

JMT101 in Combination With Osimertinib, Versus Cisplatin-pemetrexed in Participants With Locally Advanced or Metastatic Non-small Cell Lung Cancer (NSCLC) Characterized by Epithermal Growth Factor Receptor (EGFR) Exon 20ins Mutations

Local Advanced or Metastatic NSCLC
Sensorion

Not yet recruiting

A Phase I/II Clinical Trial With SENS-501 in Children Suffering From Severe to Profound Hearing Loss Due to Otoferlin (OTOF) Mutations (AUDIOGENE)

Otorhinolaryngologic Diseases | Ear Diseases | Hearing Disorders | Deafness | Hearing Loss, Sensorineural | Congenital Deafness | DFNB9 | OTOF Gene Mutation

France
Eilean Therapeutics

Not yet recruiting

Dose Escalation and Expansion Study to Evaluate the Safety, PK, PD and Efficacy of ZE46-0134 in Adults With FLT3 Mutated Relapsed or Refractory Acute Myeloid Leukemia

AML With Gene Mutations

Australia
National Cancer Center, China

Not yet recruiting

A Study With BPI-1178 and Osimertinib in Advanced Non-small Cell Lung Cancer Patients With EGFR Mutations (EGFR)

NSCLC
Tianjin Medical University Cancer Institute and...

Recruiting

Osimertinib Plus Dalpiciclib in Patients With EGFR-mutant, CDK4/6 Pathway Aberrant, Advanced Non-small Cell Lung Cancer Following Acquired Resistance to Third-generation EGFR TKI: a Phase II Trial

Non-small Cell Lung Cancer | EGFR Activating Mutation | EGFR-TKI Resistant Mutation | Cell Cycle Deregulation

China
University of Aarhus
Aarhus University Hospital

Recruiting

Circulating Tumor DNA in Peripheral T-cell Lymphomas (CIRCULATE)

Peripheral T-cell Lymphoma | NK/T-Cell Lymphoma

Denmark
Hunan Province Tumor Hospital

Not yet recruiting

Sunvozertinib Plus Anlotinib as 1L Treatment in EGFR Mutant Advanced NSCLC-RW (WUKONG-32-RW)

Non-small Cell Lung Cancer

China
Hunan Province Tumor Hospital

Not yet recruiting

Sunvozertinib Plus Anlotinib as 1L Treatment in EGFR-Sensitive Mutations Combined With Co-Mutations Advanced NSCLC (WUKONG-32)

Non-Small Cell Lung Cancer

China
Fudan University

Recruiting

Survival Validation and Gene Mutations of N Descriptors in the Ninth Edition of the TNM Classification for Lung Cancer

Non-small Cell Lung Cancer

China
AstraZeneca
Daiichi Sankyo

Not yet recruiting

Phase III, Open-label Study of First-line Osimertinib With or Without Datopotamab Deruxtecan for EGFRm Locally Advanced or Metastatic Non-small Cell Lung Cancer (TROPION-Lung14)

Non-small Cell Lung Cancer

China, Taiwan, Korea, Republic of, Australia
Washington University School of Medicine
National Cancer Institute (NCI); The Foundation for Barnes-Jewish Hospital

Recruiting

Washington University Participant Engagement and Cancer Genomic Sequencing Center (WU-PE-CGS)

Multiple Myeloma | Rectal Cancer | Cholangiocarcinoma | Colon Cancer

United States
Maximilian Stahl, MD
Syndax Pharmaceuticals

Not yet recruiting

Revumenib in Combination With 7+3 + Midostaurin in AML

Acute Myeloid Leukemia | Leukemia | AML | AML, Adult | AML With Gene Mutations

United States
M.D. Anderson Cancer Center
Aadi Bioscience

Not yet recruiting

A Phase I Trial of Combination Gemcitabine and Nab-Sirolimus in Advanced Leiomyosarcomas or Advanced Soft-Tissue Sarcomas With TSC2 or TSC1 Loss-of-function Mutations or Deletions

Leiomyosarcoma | Soft-tissue Sarcomas

United States
Liaoning Tumor Hospital & Institute

Not yet recruiting

Adebrelimab Plus Chemotherapy as Neoadjuvant Therapy in Resectable NSCLC Harboring Driver Gene Mutations

Non Small Cell Lung Cancer
Dizal Pharmaceuticals

Recruiting

A Phase II Clinical Trial of DZD9008 in Combination With AZD4205 in Standard Treatment Failed NSCLC Patients With EGFR Mutations (WU-KONG21)

Non-small Cell Lung Cancer

China
ViGeneron GmbH

Recruiting

Safety and Tolerability of Intravitreal Administration of VG901 in Patients With Retinitis Pigmentosa Due to Mutations in the CNGA1 Gene

Retinitis Pigmentosa

Germany
University of Bern
University of Zurich; University of Bristol; ETH Zurich; University of KwaZulu

Recruiting

HIV-1 Subtype-specific Drug Resistance in Patients Failing Dolutegravir (DTG) Based Regimen (DTG-Resist)

Hiv

Mexico, Malawi, Argentina, Brazil, Burkina Faso, Cambodia, Cameroon, Congo, Côte D'Ivoire, Kenya, Rwanda, Tanzania, Thailand, Uganda, Zambia, Zimbabwe
The Affiliated Hospital of Xuzhou Medical University

Recruiting

Effect of Mutations in T2DM Susceptibility Genes on the Expression of Susceptibility Genes in Patients With T2DM and Controls

Type 2 Diabetes Mellitus | Genetic Mutations | Gene Polymorphisms | Susceptibility, Genetic

China
Novartis Pharmaceuticals

Recruiting

Special Drug Use-results Surveillance of Tafinlar/Mekinist

BRAF V600E Mutation-positive Unresectable Advanced or Recurrent Solid Tumor

Japan
Iambic Therapeutics, Inc

Recruiting

A Phase 1/1b Study of IAM1363 in HER2 Cancers

HER2 Mutation-Related Tumors

United States
National Cancer Institute (NCI)

Recruiting

Autologous T-cells Genetically Engineered to Express Receptors Reactive Against KRAS Mutations in Conjunction With a Vaccine Directed Against These Antigens in Participants With Metastatic Cancer

Breast Cancer | Colorectal Cancer | Ovarian Cancer | Non-Small Cell Lung Cancer | Gastrointestinal Cancer | Genitourinary Cancer | Metastatic Solid Cancers

United States
Frontier Medicines Corporation

Recruiting

A Study Evaluating FMC-376 in Participants With KRAS G12C Mutated Solid Tumors (PROSPER)

Colorectal Cancer | Pancreatic Cancer | Non Small Cell Lung Cancer | Metastatic Solid Tumor | Solid Tumor, Adult | Unresectable Solid Tumor | KRAS G12C | Advanced Solid Tumors With KRAS G12C Mutations

United States
Washington University School of Medicine
Bristol-Myers Squibb; Damon Runyon Cancer Research Foundation

Not yet recruiting

Enasidenib for Patients With Clonal Cytopenia of Undetermined Significance and Mutations in IDH2A Decentralized Trial

Clonal Cytopenia of Undetermined Significance | CCUS Clonal Cytopenia of Undetermined Significance

United States
Suzhou Zelgen Biopharmaceuticals Co.,Ltd

Recruiting

A Study of ZG2001 in Participants With KRAS Mutated Advanced Solid Tumours

Solid Tumor | KRAS Mutation-Related Tumors

China
N.N. Petrov National Medical Research Center of...

Recruiting

Leflunomide or Combination of MEK Inhibitor and Hydroxychloroquine for Refractory Patients With RAS Mutations (NТО-RAS)

Melanoma | Lung Cancer | Pancreas Cancer | Refractory Cancer | Colorectal Cancer Recurrent | RAS Mutation | Ras (Kras or Nras) Gene Mutation

Russian Federation
City Clinical Oncology Hospital No 1
Atlas Biomed; N.N. Blokhin National Medical Research Center of Oncology; Moscow...

Recruiting

Other Oncogene Mutations for Anti-EGFR Efficacy in Patients With Left-sided RAS-wild Type Metastatic Colorectal Cancer (CRC01)

Colorectal Neoplasms | Chemotherapy Effect | Molecular Sequence Variation

Russian Federation
Innostellar Biotherapeutics Co.,Ltd

Recruiting

Fellow-eye Study (FE) of LX101 in Subjects With Inherited Retinal Dystrophy

Inherited Retinal Dystrophy

China
Manuel Coelho da Rocha

Not yet recruiting

Tailored vs. Empirical Helicobacter Pylori Infection Treatment

Helicobacter Pylori Infection

Portugal
IRCCS San Raffaele
Università Vita-Salute San Raffaele

Recruiting

Mechanisms of Somatic Mutation and Tumor Initiation in Pre-malignant Kidney Tubule Cells (SoMuKT)

Carcinoma, Renal Cell | Von Hippel-Lindau Disease

Italy
AstraZeneca

Not yet recruiting

To Evaluate the Efficacy/Safety of Osimertinib Prior to CRT and Maintenance of it With Stage III, Unresectable NSCLC With EGFR Mutations (NEOLA)

Lung Cancer

Thailand, Vietnam, Korea, Republic of, India, China, Taiwan, United States, Israel, Spain, Turkey
Sixth Affiliated Hospital, Sun Yat-sen University

Recruiting

Machine Learning Predicts Survival and Mutations in Ovarian Metastases of Colorectal Cancer

Ovarian Metastases of Colorectal Cancer

China
Cancer Institute and Hospital, Chinese Academy...

Not yet recruiting

RC48 Combined With EGFR or HER2 TKI for Locally Advanced or Metastatic NSCLC Patients With HER2 Alterations

Non Small Cell Lung Cancer | ERBB2 Mutation-Related Tumors | Disitamab Vedotin | ERBB2 Gene Duplication
IRCCS San Raffaele
IRCCS National Neurological Institute "C. Mondino" Foundation

Recruiting

Exploring Brain Molecular Imaging and Blood Biomarkers in Subjects With Glucocerebrosidase Mutations: Toward a Precision Medicine Approach to Characterize Parkinson's Disease Clinical Trajectories

Parkinson Disease

Italy
Boehringer Ingelheim

Recruiting

Beamion LUNG-2: A Study to Test Whether Zongertinib (BI 1810631) Helps People With Advanced Non-small Cell Lung Cancer With HER2 Mutations Compared With Standard Treatment

Lung Cancer, Non-squamous, Non-small Cell

Australia, Korea, Republic of, China, Japan, United States, Singapore
Shanghai Jiatan Pharmatech Co., Ltd

Recruiting

A Study of WX390 Combined With Toripalimab in Patients With Advanced Gastric-type Endocervical Adenocarcinoma With STK11 Mutations

Gastric Type Adenocarcinoma (GAS) With STK11 Mutation

China
China Medical University, China

Not yet recruiting

Chemotherapy Sequential Tislelizumab After Radical Resection in Patients With dMMR/MSI-H or POLE/POLD1 Mutations

Colorectal Adenocarcinoma | Gastric

China
UniQure Biopharma B.V.

Not yet recruiting

Safety, Tolerability, and Efficacy Study of Intrathecally Administered Gene Therapy AMT-162 in Amyotrophic Lateral Sclerosis (ALS) Patients With SOD1 Mutations

Amyotrophic Lateral Sclerosis
Shanghai YingLi Pharmaceutical Co. Ltd.

Not yet recruiting

Pan-RAS Inhibitor YL-17231 in Patients With Advanced Solid Tumors Harboring Mutations in KRAS, HRAS, or NRAS

Advanced Solid Tumors

United States
National Cancer Institute (NCI)

Recruiting

Imatinib to Increase RUNX1 Activity in Participants With Germline RUNX1 Deficiency

Inherited Bone Marrow Failure Syndrome | Familial Platelet Disorder With Predisposition to Myeloid Malignancies

United States
Yang Li
Ruijin Hospital

Recruiting

Arsenic Trioxide Combined With Chemotherapy for the Treatment of p53-mutated Pediatric Cancer

Pediatric Cancer | Li-Fraumeni Syndrome | p53 Mutations

China
University of Milano Bicocca

Recruiting

Prospective Study on Resistance-associated Mutations in Metastatic Lung Cancer (MUT-ONC)

Lung Cancer

Italy
Nanjing Sanhome Pharmaceutical, Co., Ltd.

Recruiting

SH-1028 Tablets Versus Placebo as Adjuvant Therapy in Resected Stage II-IIIB NSCLC With Sensitizing EGFR Mutations

Non-small Cell Lung Cancer

China
Stanford University

Not yet recruiting

Sirolimus for Improving Social Abilities in People With PTEN Germline Mutations

PTEN Gene Mutation | PTEN Hamartoma Tumor Syndrome | PTEN Hamartoma Syndrome

United States
Merck Sharp & Dohme LLC

Recruiting

Sacituzumab Tirumotecan (MK-2870) Versus Chemotherapy in Previously Treated Advanced or Metastatic Nonsquamous Non-small Cell Lung Cancer (NSCLC) With EGFR Mutations or Other Genomic Alterations (MK-2870-004)

Non-small Cell Lung Cancer (NSCLC)

Israel, Taiwan, United States, Australia, Hong Kong, Chile, Korea, Republic of, Canada, Malaysia
Bart Rijnders

Recruiting

Detection of Azole Resistance Inducing Mutations on DNA Extracted Directly From Serum or Plasma of Immunocompromised Patients With an Invasive Aspergillus Infection Azole Resistance PCR Optimalization-study (ARPO)

Invasive Aspergillosis

Netherlands
National University Hospital, Singapore

Not yet recruiting

Study of EGFR TKI in Patients With Advanced NSCLC Harbouring EGFR Mutations

NSCLC

Singapore
Sun Yat-sen University

Not yet recruiting

Neoadjuvant and Adjuvant Targeted Treatment in NSCLC With BRAF V600 or MET Exon 14 Mutations

NSCLC | BRAF V600 Mutation | MET Exon 14 Mutation

China
Intergroupe Francophone de Cancerologie Thoracique

Recruiting

A Prospective Cohort Study to Evaluate Molecular pRognostic Factors and Resistance Mechanisms to Osimertinib in Adjuvant Treatment of Completely Resected pIB-IIIA Non-small Cell Lung Carcinoma With Common EGFR Mutations (L858R and Del19) (ROSIE)

Non Small Cell Lung Cancer | EGFR Activating Mutation | EGFR L858R | EGFR DEL19

France

Search clinical trials for: Sarcomere Mutations

Sponsors and Collaborators

Medical Conditions

Drug Interventions

CROs by country

CROs in Oman

Conditions

Rare Diseases

Drug Interventions

Dietary Supplements

Sponsor/Collaborators

Locations